Santhera Pharmaceuticals Holding AG: Santhera gibt den ersten Handelstag der neuen Wandelanleihe an der SIX Swiss Exchange bekannt
Pratteln, Schweiz,
vorrangigen
375 mit Fälligkeit 2024 heute an der SIX Swiss Exchange beginnt.
Am 4. Mai 2021 hat die Santhera Pharmaceuticals Holding AG eine vorrangige ungesicherte Wandelanleihe mit Fälligkeit 2024 (die
Anleihe 2021/24) im Gesamtnennbetrag von CHF 30 270 375 ausgegeben.
Die Anleihe 2021/24 wurde zum Handel an der SIX Swiss Exchange zugelassen. Der erste Handelstag ist heute, der 7. Mai 2021. Das Tickersymbol der Anleihe 2021/24 lautet SAN21 und die ISIN CH0563348744.
Wie in den Anleihensbedingungen [1] festgelegt, hat die Wandlungsfrist, innert welcher ein Anleihensgläubiger das Wandelrecht für die Anleihe 2021/24 ausüben kann, am 4. Mai 2021 begonnen und endet sieben Handelstage vor dem Fälligkeitstermin am 17. August 2024 (bzw. im Falle einer vorzeitigen Rückzahlung zehn Handelstage vor dem Tag der vorzeitigen Rüc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO
Pratteln, Switzerland, May 4, 2021 – Santhera .
Santhera Pharmaceuticals Holding AG: Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024
Pratteln, Switzerland,
s the settlement of the
e
.
Santhera Pharmaceuticals Holding AG is settling today its offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the
2017/22 Bonds) on the terms set out in the Notice of Repurchase Offer dated March 25, 2021 (the
Exchange
Offer). Upon settlement, 2017/22 Bonds in the aggregate principal amount of CHF 15,155,000 remain in circulation.
Santhera will issue today Senior Unsecured Convertible Bonds due 2024 (the
2021/24 Bonds) in the aggregate principal amount of CHF 30,270,375, on the terms set out in the issuance and listing prospectus dated May 4, 2021, to those holders of the 2017/22 Bonds who accepted the Exchange Offer. The principal amount/denomination of the 2021/24 Bonds is CHF 3,375 per bond, with a conversion price of CHF 3.00 and a conversi
By Notice of Repurchase Offer dated March 25, 2021 (the
Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the
2017/22 Bonds) on the terms set out in the Notice (the
Exchange
Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation.
S
ettlement
Santhera has decided to settle the Exchange Offer on May 4, 2021. The Exchange Offer will be settled via the banking system. Upon settlement, all offer conditions (b), (c), (d) and (e), as set out in the Notice, which have not been satisfied until that date will be waived.